Eeva Piitulainen
11 – 20 of 83
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD
(
- Contribution to journal › Article
-
Mark
Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
(
- Contribution to journal › Article
- 2018
-
Mark
Deposition of inhaled nanoparticles is reduced in subjects with COPD and correlates with the extent of emphysema : Proof of concept for a novel diagnostic technique
(
- Contribution to journal › Article
-
Mark
Lung function and CT lung densitometry in 37-to 39-year-old individuals with alpha-1-antitrypsin deficiency
(
- Contribution to journal › Article
- 2017
-
Mark
Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years
(
- Contribution to journal › Article
-
Mark
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency : an open-label extension trial (RAPID-OLE)
(
- Contribution to journal › Article
-
Mark
Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
(
- Contribution to journal › Article
-
Mark
Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits
(
- Contribution to journal › Article
-
Mark
European Respiratory Society statement : Diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency
(
- Contribution to journal › Article
- 2016
-
Mark
Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
(
- Contribution to journal › Article